M
Miriam S. Maes
Researcher at Centre for Addiction and Mental Health
Publications - 8
Citations - 129
Miriam S. Maes is an academic researcher from Centre for Addiction and Mental Health. The author has contributed to research in topics: Tardive dyskinesia & Antipsychotic. The author has an hindex of 4, co-authored 6 publications receiving 72 citations. Previous affiliations of Miriam S. Maes include Sunnybrook Health Sciences Centre & University of Toronto.
Papers
More filters
Journal ArticleDOI
New findings in pharmacogenetics of schizophrenia.
TL;DR: The findings to date are promising and provide a better understanding of the development of side effects and response to antipsychotics, however, more comprehensive investigations in large, well characterized samples will bring us closer to clinically actionable findings.
Journal ArticleDOI
Genetics of tardive dyskinesia: Promising leads and ways forward.
Clement C. Zai,Miriam S. Maes,Arun K. Tiwari,Gwyneth Zai,Gary Remington,James L. Kennedy,James L. Kennedy +6 more
TL;DR: The most promising genes associated with TD are reviewed, including DRD2, DRD3, VMAT2, HSPG2,HTR2A, HTR2C, and SOD2, and evidence supporting a role for these genes from preclinical models of TD is presented.
Journal ArticleDOI
Suicide epigenetics, a review of recent progress
TL;DR: It is crucial to consider suicidal patients or suicide victims' distal and proximal past history e.g., early-life adversity and psychiatric disorder in epigenetic studies of suicidality, in order to extract more comparable and reproducible epigenetic findings in suicide.
Posted ContentDOI
The tryptophan catabolite or kynurenine pathway in Alzheimer's disease: a systematic review and meta-analysis.
Abbas F. Almulla,Thitiporn Supasitthumrong,Arisara Amrapala,Chavit Tunvirachaisakul,A.-K. K. Abdul Jaleel,G. Oxenkrug,Hussein Kadhem Al-Hakeim,Miriam S. Maes +7 more
TL;DR: AD is characterized by TRP depletion but not by an overactivity of the TRYCAT pathway, indicating that IDO-induced production of neurotoxic TRYCats is not a key factor in the pathophysiology of AD.
Journal ArticleDOI
Investigation of the HSPG2 Gene in Tardive Dyskinesia - New Data and Meta-Analysis.
Clement C. Zai,Frankie H. F. Lee,Arun K. Tiwari,Arun K. Tiwari,Justin Y. Lu,Vincenzo De Luca,Vincenzo De Luca,Miriam S. Maes,Miriam S. Maes,Deanna Herbert,Anashe Shahmirian,Sheraz Y. Cheema,Gwyneth Zai,Gwyneth Zai,Anupama Atukuri,Michael Sherman,Sajid A. Shaikh,Maria Tampakeras,Natalie Freeman,Nicole King,Daniel J. Müller,Daniel J. Müller,Lior Greenbaum,Lior Greenbaum,Bernard Lerer,Aristotle N. Voineskos,Aristotle N. Voineskos,Steven G. Potkin,Jeffrey A. Lieberman,Herbert Y. Meltzer,Gary Remington,Gary Remington,James L. Kennedy,James L. Kennedy +33 more
TL;DR: A meta-analysis specific to the relationship of HSPG2 rs2445142 with TD occurrence found a significant association of the G allele withTD occurrence (p = 0.0001); however, much of the effect appeared to originate from the discovery dataset, Nonetheless, most study samples exhibit the same trend of association with TD for theG allele.